Team:Tsinghua/Model
Safety
Home
Team
Team members
Attribution
Acknowledgement
Sponsorship
Project
Description
Design
Experimental Results
Proof of concepts
Notebooks
Modeling
Parts
Parts Summary
Basic Parts
Composite Parts
Human Practices
Collaboration
Public Engagement
Integrated Human Practices
Medal Checklist
Bronze
Silver
Gold
Home
Team
Project
Parts
Human practice
modeling
We model our system mainly by the following assumptions:
1. PAMmer and sgRNA of the target gene are abundant, so all the suvCas9 is bound with them;
$$suvCas9 + sgRNA + PAMmer \to suvCas9::sgRNA::PAMmer$$
2. The total concentration of suvCas9 (located in cytoplasm and nucleus) and the target mRNA (normal and mutated) stay the same;
$$[suvCas9::sgRNA::PAMmer(cytosolic)] + [suvCas9::sgRNA::PAMmer(nucleic)] + [mRNA(canonical)::suvCas9::sgRNA::PAMmer(cytosolic)] + [mRNA(mutated)::suvCas9::sgRNA::PAMmer(cytosolic)] = {c}_{0}$$ $$mRNA(mutated) + mRNA(canonical) = {c}_{R}$$ 3. All the related reactions, which are listed below, obey the steady-state assumption, i. e., they are in the equilibrium state; $$suvCas9::sgRNA::PAMmer(cytosolic) \to suvCas9::sgRNA::PAMmer(nucleic), {K}_{0}$$ $$mRNA(canonical) + suvCas9::sgRNA::PAMmer(cytosolic) \to mRNA(canonical)::suvCas9::sgRNA::PAMmer(cytosolic), {K}_{1}$$ $$mRNA(mutated) + suvCas9::sgRNA::PAMmer(cytosolic) \to mRNA(mutated)::suvCas9::sgRNA::PAMmer(cytosolic), {K}_{2}$$ 4. After binding with mRNA, the suvCas9 complex cannot enter the nucleus; Using the above mentioned assumptions, we can know: $$[suvCas9::sgRNA::PAMmer(nucleic)] = \frac{{K}_{0}}{1 + {K}_{0} + {K}_{1}[mRNA(canonical)] + {K}_{2}[mRNA(mutated)]} \times {c}_{0}......(1)$$ We also assume: $$[mRNA(mutated)] = \alpha \times {c}_{R}$$ $$[mRNA(canonical)] = (1- \alpha) \times {c}_{R}$$ $${K}_{1} = t \times {K}_{2}, t >> 1$$ In fact: $${K}_{0} >> 1$$ So, the equation (1) can be modified to: $$[suvCas9::sgRNA::PAMmer(nucleic)] / {c}_{0} = \frac{{K}_{0}}{{K}_{2}{c}_{R}(1 - t)\alpha + {K}_{2}{c}_{R}t + {K}_{0}}......(2)$$ The equation (2) is plotted below: The relation between suvCas9::sgRNA::PAMmer(nucleic) and thymidine kinase(TK) expression is linear in the working condition: $$[TK] = {k}_{0}[suvCas9::sgRNA::PAMmer(nucleic)]......(3)$$ We assume a sigmoid function between [TK] and probability of cell death: $$P(cell death) = \frac{1}{1 + e^{-{k}_{1}[TK] + {k}_{2}}}......(4)$$ Integrating the equation (2), (3) and (4), we get: $$P(cell death) = \frac{1}{1 + e^{{k}_{2} - {c}_{0}{k}_{0}{k}_{1}\frac{{K}_{0}}{{K}_{2}{c}_{R}(1 - t)\alpha + {K}_{2}{c}_{R}t + {K}_{0}}}}$$ It can also be written in the logarithm relative risk format: $$log(\frac{P(cell death)}{1 - P(cell death)}) = {c}_{0}{k}_{0}{k}_{1}\frac{{K}_{0}}{{K}_{2}{c}_{R}(1 - t)\alpha + {K}_{2}{c}_{R}t + {K}_{0}} - {k}_{2}$$ In this final equation, we can modify several parameters: ${c}_{0}, {k}_{0}$ by the following method: ${c}_{0}$: By changing the suvCas9 promotor and terminator. ${k}_{0}$: By changing the inducible promotor of the TK gene